Improving vaccines to prevent tuberculosis
ADVANCING VACCINE ADJUVANT RESEARCH FOR TUBERCULOSIS (AVAR-T)
['FUNDING_OTHER'] · UNIVERSITY OF SYDNEY · NIH-10703854
This study is working on creating better vaccines for tuberculosis, especially for people at higher risk like those with HIV, by testing different ingredients that help boost the vaccine's effectiveness, so we can find the best options to protect against TB.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SYDNEY (nih funded) |
| Locations | 1 site (SYDNEY, AUSTRALIA) |
| Trial ID | NIH-10703854 on ClinicalTrials.gov |
What this research studies
This research focuses on developing better vaccines for tuberculosis (TB), particularly for individuals at higher risk, such as those living with HIV. The team will compare different vaccine adjuvants, which are substances that enhance the body's immune response to the vaccine, alongside specific TB antigens. By using mouse models and non-human primates, they aim to identify the most effective combinations of adjuvants and antigens that could lead to improved vaccine candidates. The ultimate goal is to create vaccines that can prevent TB infection and improve outcomes for those already affected.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for tuberculosis, particularly those living with HIV.
Not a fit: Patients who are not at risk for tuberculosis or who have already been vaccinated with effective TB vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that significantly reduce the incidence of tuberculosis, especially in vulnerable populations.
How similar studies have performed: Previous research has shown promise in developing effective vaccine adjuvants for other diseases, suggesting potential success for this approach in tuberculosis.
Where this research is happening
SYDNEY, AUSTRALIA
- UNIVERSITY OF SYDNEY — SYDNEY, AUSTRALIA (ACTIVE)
Researchers
- Principal investigator: BRITTON, WARWICK — UNIVERSITY OF SYDNEY
- Study coordinator: BRITTON, WARWICK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Disease, Disorder, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus